4-MeO-PCE (4-Methoxyeticyclidine) is a lesser-known dissociative compound belonging to the arylcyclohexylamine family. Structurally related to PCP and ketamine, it functions as an NMDA receptor antagonist, disrupting typical signal transmission between neurons. In research contexts, it is studied for its ability to induce dissociative, anesthetic, and psychoactive effects. Though it remains unscheduled in many countries, its use is strictly for analytical and laboratory purposes—not for human consumption.

• NMDA Receptor Antagonist
  4-MeO-PCE primarily blocks N-methyl-D-aspartate (NMDA) receptors in the brain, which are critical for memory, perception, and pain response. By interfering with glutamatergic signaling, the compound induces dissociative effects such as detachment from physical and emotional sensations.

• Arylcyclohexylamine Class
  This compound belongs to the same class as ketamine and PCP, sharing core structural motifs. It has a cyclohexane ring bonded to an amine group, making it suitable for comparative research into NMDA-mediated neuroactivity.

• Dissociative and Psychoactive Profile
  Its effects often include depersonalization, altered sensory input, reduced motor control, and a dream-like cognitive state. At higher doses, 4-MeO-PCE has been reported to induce deep dissociation and sensory isolation.

• Oral and Intranasal Activity
  In laboratory settings, 4-MeO-PCE is effective via both oral and intranasal administration in animal models. These routes have been examined for onset time, intensity of dissociation, and metabolic behavior.

• Non-Serotonergic Activity
  Unlike classical psychedelics, 4-MeO-PCE does not primarily interact with serotonin receptors (such as 5-HT2A), making its mechanism distinct. Its effects are more anesthetic and sedative rather than hallucinogenic or empathogenic.

• Potential Tool for Neuropsychological Studies
  Due to its ability to alter perception and sensory input, it may be studied to better understand dissociative states, altered consciousness, and NMDA receptor dysfunction in neurological disorders.

• Structural Similarity to 3-MeO-PCE
  Although 4-MeO-PCE is chemically similar to 3-MeO-PCE, subtle variations in substitution placement result in different subjective and pharmacokinetic profiles, which are useful in SAR (Structure-Activity Relationship) studies.

The legal status of 4-MeO-PCE varies significantly depending on national and regional regulations. In many jurisdictions, it is unscheduled and can be purchased legally for research purposes. However, some countries classify it under analogue laws or specific chemical bans. Buyers must conduct due diligence before purchasing to ensure compliance with local regulations.

• Unscheduled in Several Countries
  In countries such as the United States (federal level), Canada, and parts of the EU, 4-MeO-PCE is not explicitly listed as a controlled substance. This makes it legally accessible for research or analytical use, although state or provincial laws may differ.

• Analog Acts and Blanket Bans
  Some regions have analogue legislation that can criminalize possession or sale of substances that are structurally or functionally similar to already banned drugs (e.g., PCP). Even if not scheduled, 4-MeO-PCE might fall under these provisions.

• Country-Specific Regulations
  Nations like the United Kingdom or Australia may regulate compounds like 4-MeO-PCE under psychoactive substance laws, making unauthorized sale or import illegal regardless of its chemical schedule.

• For Research Use Only
  Psycho Plug sells 4-MeO-PCE strictly for laboratory, analytical, or forensic research. We do not promote or support human consumption, ensuring our operation remains legally compliant in our regions of operation.

• Customs and Import Risk Awareness
  While we offer global shipping, buyers must take full responsibility for knowing whether their country allows importation of this compound. We advise checking with local customs agencies or legal professionals before ordering.

• Shipping Restrictions Applied
  We do not ship to countries or regions where 4-MeO-PCE is known to be banned or where we’ve had consistent customs seizures. Our system will alert you at checkout if your region is excluded.

• High Success Rate with Discreet Shipping
  Even in gray-area regions, our stealth packaging has led to over 98% successful delivery rate due to our non-branded, tamper-evident shipping methods.

In documented research, 4-MeO-PCE produces a distinct dissociative experience, characterized by sensory detachment, emotional flattening, and altered temporal awareness. Unlike hallucinogens, it typically does not cause vivid visuals, but rather shifts in body perception and cognition. Its effects make it useful for examining states of consciousness and neurochemical interference with perception.

• Moderate to Strong Dissociation
  Users often report a sensation of being disconnected from their physical body or surroundings. This detachment can be both physical (loss of bodily awareness) and psychological (emotional numbness).

• Dream-like or “Floaty” Mental State
  At common doses, 4-MeO-PCE produces a surreal state that some researchers liken to lucid dreaming. This quality makes it particularly interesting for studying altered awareness without full unconsciousness.

• Cognitive Impairment and Slow Thought Patterns
  It may slow internal dialogue and interfere with speech fluency, working memory, and real-time problem solving—effects common to NMDA antagonists.

• Visual and Auditory Alterations
  While not overtly hallucinogenic, some visual flickering, auditory distortions, and spatial warping have been reported in exploratory research contexts.

• Dose-Dependent Motor Effects
  At low doses, coordination may be mildly impaired. Higher doses can result in a loss of balance, delayed reaction time, or inability to stand or move effectively.

• Emotional Blunting
  A marked reduction in emotional reactivity or empathy may occur. This flattening can be useful in studying emotional processing or neurological disorders involving affect regulation.

• Mild Euphoria or Neutral Mood Shift
  Depending on setting and dosage, some subjects may experience a subtle sense of peace or contentment, though the compound is not typically described as euphoric.

There is no universal “ideal” dose for 4-MeO-PCE, but multiple research case studies and anecdotal logs suggest a clear dose-response relationship. Dosage depends on the route of administration, the purpose of the research, and the desired depth of dissociation. Accurate measurement is essential due to its high potency and potential for psychological impairment.

• Threshold Dose: 3–5 mg (Oral)
  This is the minimum effective dose where very light dissociative effects may become noticeable. At this level, motor coordination is largely unaffected, but subtle cognitive shifts may occur.

• Common Research Range: 10–25 mg (Oral)
  This range is often used for moderate dissociative research. It yields significant perceptual changes without completely incapacitating the subject.

• Higher Dose Exploration: 25–35 mg (Oral)
  At this range, effects intensify, and subjects often report near-total detachment and temporary loss of body perception. Ideal only for deep, controlled observation sessions.

• Intranasal Administration: 5–20 mg
  Due to faster onset and stronger intensity, intranasal doses are often lower. Absorption is quicker, but the experience can be more jarring and less predictable.

• Equipment Accuracy is Critical
  Always use a 0.001g (1 mg) scale for precise weighing. Microgram errors can result in overexposure or misleading data.

• Start Low, Go Slow
  Especially with novel compounds, a conservative dose is advised to establish a safety baseline and understand subject response.

• Consider Individual Variables
  Body mass, metabolism, neurochemistry, and past substance exposure may all affect how a subject responds to 4-MeO-PCE. No one-size-fits-all dose exists.

Proper storage of 4-MeO-PCE is critical for maintaining its potency, purity, and chemical integrity. Because this compound is sensitive to moisture and light, careful handling and containment will ensure a longer shelf life and more reliable experimental results.

• Use Airtight, Opaque Containers
  Store the compound in glass or high-density polyethylene containers with airtight seals. UV-resistant (amber) containers are preferable to protect from light damage.

• Avoid Humidity
  Moisture can degrade the compound or cause clumping. Include silica gel desiccants in the container if storing long-term, especially in humid environments.

• Keep in a Cool, Dry Place
  Store in a room-temperature location away from direct sunlight. Refrigeration is unnecessary unless specified by the manufacturer but can be used for long-term storage if sealed tightly.

• Minimize Air Exposure
  Each time the container is opened, oxidation can occur. Divide bulk purchases into smaller sealed units if frequent access is needed.

• Label Clearly
  Properly label containers with the compound name, concentration (if applicable), date of acquisition, and any safety data. This is crucial for laboratory compliance and personal safety.

• Avoid Cross-Contamination
  Do not store near reactive substances, including acids or volatile chemicals. Store 4-MeO-PCE separately from other research compounds.

• Check for Degradation
  If discoloration, odor changes, or clumping occurs, the material may be compromised. Re-analyze or discard safely if in doubt.

Although 4-MeO-PCE is used primarily in research, it presents a variety of risks—especially if handled improperly or used outside of controlled conditions. Its dissociative effects can impair cognition, coordination, and decision-making, making it essential to understand and mitigate potential hazards before any experimental use.

• Cognitive Disruption and Disorientation
  One of the primary risks is short-term confusion, memory impairment, or derealization. In research settings, subjects often report losing track of time or space, which can lead to distress or unsafe behavior if unmonitored.

• Loss of Motor Control
  At higher doses, 4-MeO-PCE significantly impairs balance, coordination, and reflexes. This makes physical injuries more likely if the subject is left unsupervised during testing.

• Emotional Flattening and Detachment
  The compound’s ability to numb emotions can sometimes trigger anxiety or psychological discomfort, especially in subjects unaccustomed to dissociative states. Emotional blunting may last beyond the main active phase.

• Potential for Psychological Dependence
  While physical addiction is unlikely, some individuals may develop a psychological reliance on dissociative states, seeking repeated sessions for emotional escape or mental disengagement.

• Unknown Long-Term Health Effects
  There are limited formal studies on chronic exposure. Long-term use may lead to cognitive dulling, persistent depersonalization, or executive dysfunction, similar to those observed in frequent ketamine users.

• Increased Risk When Combined with Other Substances
  Mixing 4-MeO-PCE with depressants (like alcohol or opioids) can dangerously suppress respiration or lead to unconsciousness. Interactions with serotonergic substances can increase the risk of serotonin syndrome.

• Unpredictable Dose Sensitivity
  Individual reactions vary widely. A dose that causes mild effects in one subject may result in overwhelming dissociation in another, emphasizing the need for gradual titration and observation.

• Improper Handling and Measurement
  Without precision scales, users risk overdosing. Even 5–10 mg differences can dramatically change the subjective experience and safety profile.

Combining 4-MeO-PCE with other substances is not recommended due to the potential for dangerous interactions, amplified side effects, and unpredictable mental or physical responses. Researchers should exercise extreme caution and consult available toxicological literature before any polypharmacy studies.

• Increased Sedation with CNS Depressants
  Combining 4-MeO-PCE with alcohol, benzodiazepines, or opioids greatly enhances sedative effects, raising the risk of respiratory depression, loss of consciousness, or blackouts.

• Unpredictable Reactions with Stimulants
  Using stimulants such as amphetamines or cocaine alongside dissociatives can lead to increased heart rate, anxiety, and cognitive dissonance. The contrasting mechanisms of stimulation and dissociation may cause panic or psychosis.

• Dangerous Serotonergic Interactions
  While 4-MeO-PCE does not primarily act on serotonin receptors, combining it with serotonergic drugs (such as SSRIs or MDMA) may alter perception unpredictably or contribute to serotonin overload in vulnerable individuals.

• Higher Risk of Delirium
  Multi-drug combinations may produce hyperactive delirium, confusion, or hallucinations not typically associated with 4-MeO-PCE alone. This has been reported in several trip logs involving combined dissociative intake.

• Impaired Risk Assessment
  The compound’s effects on decision-making are amplified when other substances are involved, increasing the chance of reckless behavior or physical accidents.

• Lack of Scientific Research on Interactions
  Few controlled studies exist on 4-MeO-PCE poly-substance interactions. This makes outcomes harder to predict and increases the risk of unexpected toxicity or adverse psychological reactions.

• Safer to Test in Isolation
  For safety and data clarity, all research involving 4-MeO-PCE should initially isolate it as the sole compound being studied. Baseline response must be clearly understood before introducing variables.

Although both compounds belong to the same class and share a similar molecular backbone, 4-MeO-PCE and 3-MeO-PCE differ significantly in their subjective effects, potency, duration, and research application. Understanding these differences is critical for dose planning and outcome prediction in analytical studies.

• Positional Isomerism
  The key difference lies in the location of the methoxy group. In 4-MeO-PCE, the methoxy group is attached to the 4-position of the aromatic ring, while in 3-MeO-PCE, it’s at the 3-position. This minor structural variation results in different binding affinities and pharmacodynamics.

• Subjective Effects
  4-MeO-PCE is generally more sedating and introspective, often producing a heavier body load and more dream-like detachment. 3-MeO-PCE, by contrast, is clearer, more stimulating, and considered more functional for tasks or social engagement.

• Potency and Duration
  3-MeO-PCE tends to have a stronger onset and longer duration (6–8 hours), whereas 4-MeO-PCE usually lasts 4–6 hours with a smoother, slower peak.

• Cognitive Impact
  Users report that 3-MeO-PCE induces more pronounced mental stimulation and complex thought patterns. 4-MeO-PCE tends to mute cognitive engagement, leading to passive dissociation and emotional flattening.

• Motor Coordination
  3-MeO-PCE is more likely to preserve mobility at moderate doses, making it easier to function during a session. 4-MeO-PCE often impairs coordination and can make physical tasks challenging.

• Research Use Cases
  4-MeO-PCE may be better suited for sedation, sensory detachment, or modeling states of unconscious processing. 3-MeO-PCE is more versatile for experiments involving interaction, cognition, or multitasking.

• Tolerance Profiles
  Anecdotally, 3-MeO-PCE builds tolerance more quickly than 4-MeO-PCE, though both compounds should be spaced out in repeated research to maintain integrity of results.

No—4-MeO-PCE is not safe for use in animals or pets under any circumstance. It is a potent dissociative compound with unpredictable effects and lacks any recognized veterinary or pharmacological use in non-human subjects. Exposure, even accidental, can be harmful or fatal.

• Toxic to Animals
  The compound’s pharmacokinetics in animals are not well understood. Ingestion, inhalation, or dermal exposure could cause neurological damage, distress, or death in small animals.

• Lack of Veterinary Approval
  4-MeO-PCE is not approved for veterinary medicine or animal behavioral research. No dosage or administration guidelines exist for animal studies.

• Accidental Ingestion Risk
  Pets may lick, sniff, or chew containers if not properly sealed. Even trace amounts can cause severe reactions such as vomiting, seizures, or loss of consciousness.

• No Antidote or Reversal Agent
  If a pet ingests 4-MeO-PCE, emergency veterinary care is required. However, no direct antidote exists, and treatment would be purely supportive.

• Secure Storage is Mandatory
  Store all dissociatives, including 4-MeO-PCE, in tamper-proof, high-level storage areas out of reach of animals and children. Improper storage increases liability.

• Do Not Use in Animal Research
  Ethical guidelines prohibit the use of such compounds in animal testing without rigorous justification and formal oversight. There is no current research framework supporting its safe use in non-human models.

• Potential for Long-Term Harm
  Even subclinical exposure can affect neurological development in pets or lab animals, leading to behavioral changes, anxiety, or physical dysfunction over time.

The active effects of 4-MeO-PCE typically last between 4 to 6 hours, depending on the dose, route of administration, and individual metabolism. However, its metabolites may remain in the body for longer, and its detectability in bodily fluids depends on the sensitivity of testing equipment used.

• Primary Effects Duration
  Dissociative effects usually peak within 1–2 hours after oral administration and taper off by 6 hours. Intranasal use can result in a quicker, more intense onset that wears off faster.

• Metabolic Half-Life
  While exact half-life data is limited, anecdotal evidence suggests it may range between 3 to 6 hours. Full elimination likely occurs within 24–48 hours in most healthy individuals.

• Residual Cognitive Fog
  Some researchers have noted a lingering “afterglow” or cognitive fog lasting 6–12 hours after the main effects fade. This includes slowed thought processes and reduced focus.

• Factors Affecting Clearance
  Age, liver function, hydration levels, and concurrent substance use can all influence how long the compound stays in the system.

• No Standard Drug Panel Detection
  4-MeO-PCE is not part of standard drug tests (e.g., SAMHSA-5), but may show up on specialized panels using GC-MS or LC-MS if those tests are designed to detect arylcyclohexylamines.

• False Positives Possible
  There is potential for false positives in tests for PCP due to structural similarity, although confirmatory testing would differentiate them.

• Persistence in Hair or Fat Tissues
  Like many synthetic compounds, small traces may be detectable in hair samples or fatty tissues for weeks, although this is uncommon outside of forensic settings.

4-MeO-PCE is not commonly targeted in standard employment or roadside drug screenings, which typically test for substances like THC, cocaine, opiates, amphetamines, and benzodiazepines. However, it may be detectable through more advanced or specialized toxicological analysis.

• Not Included in Standard Panels
  Most basic 5-panel or 10-panel drug tests used by employers or probation programs do not screen for dissociatives like 4-MeO-PCE. It remains undetected unless the testing protocol is specifically designed to identify it.

• May Trigger False Positives for PCP
  Due to structural similarities with PCP, 4-MeO-PCE might result in a false positive under older or less specific immunoassay methods. Confirmatory testing using GC-MS or LC-MS would be required to differentiate it.

• Specialized Testing Required
  Laboratories with advanced testing capabilities may detect 4-MeO-PCE and its metabolites using liquid chromatography-mass spectrometry (LC-MS) or gas chromatography-mass spectrometry (GC-MS), especially in forensic or clinical settings.

• Short Detection Window
  Given its estimated half-life, the compound is typically metabolized and excreted within 24–48 hours in healthy individuals, meaning its detectability is time-limited unless hair or tissue samples are tested.

• Not Typically Screened in Routine Medical Exams
  Unless there’s suspicion of dissociative use or overdose, 4-MeO-PCE is not included in typical toxicology panels during hospital visits or clinical assessments.

• Unlikely to Be Detected Without Cause
  If no behavioral signs or reasons prompt advanced testing, the presence of 4-MeO-PCE usually goes unnoticed in standard drug monitoring environments.

• Forensic Testing May Include It
  In criminal investigations or post-mortem cases where dissociative intoxication is suspected, forensic labs may include 4-MeO-PCE in a broader panel of designer drugs.

4-MeO-PCE is not suitable for microdosing, as it does not exhibit the neurocognitive enhancement or subtle perceptual benefits typically associated with classical psychedelics like LSD or psilocybin. Its pharmacological profile is more dissociative and sedative, making it inappropriate for regular sub-perceptual use.

• Not a Classical Psychedelic
  Unlike serotonergic psychedelics used in microdosing regimens, 4-MeO-PCE does not enhance sensory clarity or mood at low doses. Its effects are generally dissociative, which may impair function.

• Sub-Threshold Effects Still Disruptive
  Even small doses (2–5 mg) can cause lightheadedness, motor incoordination, and cognitive disruption, which can interfere with work, communication, or emotional regulation.

• No Documented Cognitive Benefits
  There is no scientific or anecdotal support for sustained creativity, focus, or empathy from microdoses of 4-MeO-PCE. In fact, repeated use may impair memory or executive function.

• Increased Risk of Tolerance and Dependence
  Microdosing on a routine schedule can lead to rapid tolerance build-up. With dissociatives, repeated low doses may result in emotional detachment or psychological dullness over time.

• Lack of Long-Term Research
  Unlike LSD or psilocybin, there are no clinical trials or long-term observational studies validating the safety or efficacy of microdosing 4-MeO-PCE.

• Difficulty in Accurate Dosing
  At very low levels (under 5 mg), tiny errors in measurement can result in noticeable and potentially unpleasant effects. Microgram precision is required, which most users may lack.

• Better Reserved for Occasional Controlled Use
  Due to its unique properties, 4-MeO-PCE is better suited for intermittent deep-dive analytical or introspective sessions, not as a daily or semi-daily microdose agent.

4-MeO-PCE occupies a distinctive place in the dissociative landscape due to its combination of physical sedation, cognitive clarity, and prolonged, immersive states of detachment. It offers an experience that sits between the “clinical” feel of ketamine and the stimulating complexity of compounds like 3-MeO-PCP.

• Balanced Dissociation and Tranquility
  Unlike many dissociatives that overwhelm the senses or induce manic stimulation, 4-MeO-PCE is often described as calm, steady, and dreamlike, creating an ideal state for reflection or non-invasive research.

• Longer Duration Than Ketamine
  While ketamine typically lasts 1–2 hours, 4-MeO-PCE can provide a stable window of altered consciousness for 4–6 hours, making it useful for longer observation periods or deep research sessions.

• Smooth Onset and Gentle Peak
  The transition into dissociation tends to be gradual rather than abrupt. This makes it more manageable for controlled lab settings and avoids the shock some subjects experience with other fast-acting dissociatives.

• Neutral Emotional Profile
  4-MeO-PCE lacks the emotional highs of empathogens or the chaotic variability of certain hallucinogens. Its consistent, emotionally flattened state is useful for studying raw perception and altered sensorimotor response.

• Less Visual Distortion
  It produces fewer visuals or geometric hallucinations compared to classic hallucinogens or even PCP analogs. This allows for clearer cognitive tracking during experiments.

• Ideal for Observing Internal States
  Its introspective nature makes it useful in experiments that require focus on internal dialogue, thought loops, and dissociative body-mind separation.

• Lower Incidence of Psychotic Reactions
  Compared to compounds like 3-MeO-PCP, 4-MeO-PCE is less likely to induce paranoia, agitation, or delusional thinking—especially at moderate doses.

Long-term effects of 4-MeO-PCE are not thoroughly researched due to its status as a novel psychoactive substance. However, based on what is known from related dissociatives, there are legitimate concerns about cognitive, emotional, and neurological impact from prolonged or repeated exposure.

• Potential Memory Impairment
  Chronic use of NMDA antagonists can disrupt memory formation and recall. Users of similar compounds have reported short-term memory loss and decreased ability to focus over time.

• Cumulative Dissociative Tolerance
  Repeated use may lead to rapid tolerance, requiring higher doses to achieve the same effect. This can increase the likelihood of psychological side effects and risky behavior.

• Persistent Depersonalization or Derealization
  Some subjects may experience lingering feelings of emotional disconnection or unreality, even days or weeks after cessation, especially after repeated high-dose exposure.

• Mood Dysregulation
  Emotional flatness or numbness may persist beyond the acute effects, potentially impacting relationships, motivation, and mood balance.

• Unknown Neurotoxicity Profile
  While ketamine has been shown to affect bladder health and cause potential neurotoxicity in high doses, 4-MeO-PCE has not undergone the same safety studies, leaving its long-term neurological safety unclear.

• Risk of Habitual Use
  Although not physically addictive, the tranquil detachment it induces may become habit-forming, particularly in individuals seeking escape from emotional stress or trauma.

• Cross-Tolerance with Other Dissociatives
  Prolonged use may reduce sensitivity not just to 4-MeO-PCE but to other arylcyclohexylamines, making subsequent research less effective due to blunted responsiveness.

At Psycho Plug, we pride ourselves on offering research chemicals of the highest purity and consistency. Our 4-MeO-PCE is professionally synthesized, independently tested, and packaged under sterile, controlled conditions to maintain integrity from lab to delivery.

• ≥99% Verified Purity
  Every batch is analyzed by third-party laboratories using GC-MS and HPLC techniques to confirm it meets or exceeds 99% chemical purity. We reject any lot that does not meet our standards.

• Free from Cutting Agents or Contaminants
  Our 4-MeO-PCE is sold in its pure, unadulterated crystalline form—no fillers, binders, or unknown substances are added. This ensures consistent, replicable results in research environments.

• Independent Lab Reports Available
  Upon request, we provide Certificates of Analysis (CoA) for transparency. These include detailed breakdowns of composition, impurity levels, and test methodology.

• Tamper-Proof, Hygienic Packaging
  All quantities are vacuum-sealed in sterile, heat-resistant foil pouches and packed in contamination-free environments. This prevents moisture or oxygen exposure during shipping.

• Consistent Batch Identity
  We track and label each batch with a unique identifier for quality assurance. This allows researchers to repeat studies with materials from the same synthesis lot if desired.

• ISO-Compliant Manufacturing
  Our synthesis partners adhere to ISO standards and follow rigorous quality control protocols, including sterilization, contamination testing, and final-stage crystallization checks.

• Fresh and Recently Synthesized
  We do not ship outdated or degraded material. Our product rotates quickly due to demand, ensuring every shipment contains a recent and stable batch.